Corticosteroids for severe community-acquired pneumonia: Not for everyone

JAMA - Journal of the American Medical Association

Volumn 313, Issue 7, 2015, Pages 673-674

  Wunderink, Richard G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; MACROLIDE; METHYLPREDNISOLONE; PLACEBO; ANTIINFLAMMATORY AGENT; CYTOKINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BACTERIAL LOAD; COMMUNITY ACQUIRED PNEUMONIA; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TREATMENT FAILURE; EDITORIAL; HERXHEIMER REACTION; HUMAN; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SEPTIC SHOCK; TREATMENT DURATION; BLOOD; FEMALE; MALE; PNEUMONIA;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; PNEUMONIA;

EID: 84923170019     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.115     Document Type: Editorial

References (15)

1. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005; 171(3):242-248.
2. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [published correction appears in JAMA. 2008;300(14):1652]. JAMA. 2002;288(7):862-871.
3. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
4. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987; 317(25):1565-1570.
5. Steinberg KP, Hudson LD, Goodman RB, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16): 1671-1684.
6. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. doi:10.1001/jama.2015.88.
7. Menéndez R, Torres A, Zalacaín R, et al; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960-965.
8. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008;63 (5):447-452.
9. Lisboa T, Blot S, Waterer GW, et al; Community-Acquired Pneumonia Intensive Care Units Study Investigators. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2009;135(1):165-172.
10. Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe communityacquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894-1901.
11. Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2003;36(4):389-395.
12. Rello J, Lisboa T, Lujan M, et al; DNA-Neumococo Study Group. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest. 2009;136(3):832-840.
13. de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20): 1549-1556.
14. Darton T, Guiver M, Naylor S, et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis. 2009;48(5):587-594.
15. Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med. 2014;42(7):1714-1721.